Results 41 to 50 of about 14,351 (208)
, 2013 A 33 year old primagravida rhesus positive woman was referred to the Emergency Department by her family doctor at 27 weeks gestation. At 25 weeks of gestation, she had been diagnosed with hypertension and was started on labetalol therapy.
Bugeja, Roberta, Galdes, Caroline
core
Archives of Anesthesia and Critical Care, 2020 Background: The aim of this study was to assess the quality of the surgical field, amount of blood loss, and duration of surgery following induced hypotension with labetalol, nitroglycerin, and high dose propofol in patients undergoing FESS under general
Seyed Mohammad Mireskandari +11 more
doaj +1 more source
The effect of intravenous labetalol administration on hemodynamic responses during desflurane inhalation [PDF]
Korean Journal of Anesthesiology, 2012 BackgroundInspired concentrations of desflurane ≥ 1 minimum alveolar anesthetic concentration (MAC) have been related to sympathetic stimulation such as hypertension and tachycardia.
Hyun-Seok Do +3 more
doaj +1 more source
Journal of Family Medicine and Primary Care, 2023 Hypertensive disorders of pregnancy affect 5% to 10% of all pregnancies globally. The aim of treatment is to bring down blood pressure (BP) quickly and smoothly, which is safe for the mother and baby.
Manika Agarwal +4 more
doaj +1 more source
Dialysis and Pregnancy: Optimizing Therapy for Best Maternal and Fetal Outcomes
Hemodialysis International, EarlyView.ABSTRACT Pregnancy in women with end‐stage kidney disease (ESKD) requiring dialysis remains high risk, with significant maternal and fetal complications. While fertility rates are markedly reduced in this population, advances in dialysis care and obstetric management have led to increasing reports of successful pregnancies.
Shreepriya Mangalgi, Silvi Shah
wiley +1 more source
A Practical Understanding of Preeclampsia for a Nurse in a Third World Setting [PDF]
, 2019 Preeclampsia is a disease of pregnancy that affects approximately 3-5% of women with child. It is one of the primary causes of mortality in mothers and babies across the globe. The exact cause, pathogenesis, or disease progression is unknown.
Lovin, Anna
core +1 more source
Micro-RNA family that modulates fibrosis and uses thereof [PDF]
, 2017 The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response
Olson, Eric N., van Rooij, Eva
core +1 more source
Health Science Reports, Volume 9, Issue 3, March 2026.ABSTRACT Background According to global projections, by the year 2050, ischemic heart disease will remain the leading cause of cardiovascular deaths with hypertension as a leading modifiable risk factor for mortality. Improving quality care for patients with acute myocardial infarction (MI) is associated with improved outcomes. Aims There is inadequate
Banaz Sadiq Elias +2 more
wiley +1 more source
Is personalized medicine achievable in obstetrics? [PDF]
, 2014 Personalized medicine seeks to identify the right dose of the right drug for the right patient at the right time. Typically, individualization of therapy is based on the pharmacogenomic makeup of the individual and environmental factors that alter drug ...
Flockhart, David A. +2 more
core +1 more source
A Facile Protocol for C(sp2)–C(sp3) Bond Formation Reactions Toward Functionalized E3 Ligase Ligands
ChemMedChem, Volume 21, Issue 4, 25 February 2026.A robust C(sp2)–C(sp3) decarboxylative coupling strategy enables access to new CRBN ligands and degraders with improved physicochemical properties. This synthetic approach is expanding the chemical space beyond C(sp2)–N linkages, fine‐tuning proteolysis‐targeting chimera activities and unlocking previously inaccessible degrader chemotypes.
Anita Maksutova +15 more
wiley +1 more source